» Articles » PMID: 7541452

Hodgkin's Disease and Human Immunodeficiency Virus Infection: Clinicopathologic and Virologic Features of 114 Patients from the Italian Cooperative Group on AIDS and Tumors

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1995 Jul 1
PMID 7541452
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To describe virologic, clinicopathologic, and therapeutic features of a large series of Italian patients with Hodgkin's disease (HD) and human immunodeficiency virus (HIV) infection.

Patients And Methods: From November 1986 to March 1994, 114 cases were observed. The relationship between Epstein-Barr virus (EBV) and HD was determined by an in situ hybridization technique, immunostaining for EBV-encoded latent membrane protein-1 (LMP-1) expression, and Southern blotting. Twenty-six patients were included in a prospective study evaluating the combination of chemotherapy (CT) with zidovudine.

Results: Combined approach on EBV study revealed that 14 (78%) of 18 patients were EBV-associated. An almost equivalent distribution of EBV subtypes was observed in EBV-carrying cases, indicating that in the HIV setting, type 2 EBV also may be pathogenetically involved in HD development. In comparing these 114 patients with our single-institutional series of 104 HIV-negative patients with HD, we observed at presentation a younger median age (29 v 38 years); a prevalence of males (90% v 56%); and a higher percentage of stage IV disease (52% v 15%), presence of B symptoms (77% v 35%), and extranodal disease (63% v 29%). The complete remission (CR) rate (58%) and median survival (13 months) of patients treated prospectively were similar to that of patients treated with standard CT regimens. The statistically significant favorable prognostic factors for survival being the following: achievement of CR, CD4+ count greater than 250/microL, and no prior diagnosis of AIDS at onset of HD.

Conclusion: Our virologic findings indicate that HIV-related HD is more closely associated with EBV than HD in the general population. The peculiar clinicopathologic findings, the role of some prognostic factors, and the possibility of cure of HIV-related HD have been demonstrated.

Citing Articles

HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.

Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A, Musimar Z JCO Glob Oncol. 2022; 8:e2100163.

PMID: 35025689 PMC: 8769145. DOI: 10.1200/GO.21.00163.


A Case of False-Positive HIV Test in a Patient With Newly Diagnosed Hodgkin Lymphoma and Literature Review.

Bukhari S, Dirweesh A, Amodu A, Nadeem M, Wallach S Cureus. 2020; 12(10):e10884.

PMID: 33178536 PMC: 7652365. DOI: 10.7759/cureus.10884.


The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.

Meti N, Esfahani K, Johnson N Cancers (Basel). 2018; 10(6).

PMID: 29914088 PMC: 6025119. DOI: 10.3390/cancers10060204.


Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.

Shepherd L, Ryom L, Law M, Hatleberg C, De Wit S, Monforte A J Natl Cancer Inst. 2017; 110(6):598-607.

PMID: 29267895 PMC: 6693037. DOI: 10.1093/jnci/djx249.


Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development.

Yasunaga J, Matsuoka M Cancer Sci. 2017; 109(1):24-32.

PMID: 29143406 PMC: 5765297. DOI: 10.1111/cas.13443.